Rocket Pharmaceuticals Announces Positive Clinical Safety Update From Initial Three Patients Treated With Rp-A501 Under Modified Phase 2 Protocol For Danon Disease
RCKT•Clinical safety update for Rp-A501 in Danon disease
Aug. 3 (Reuters) - Rocket Pharmaceuticals Inc. (RCKT.O):
- Rocket Pharmaceuticals announces positive clinical safety update from initial three patients treated with RP-A501 under modified Phase 2 protocol for Danon disease
- RP-A501 well-tolerated in initial three patients with no TMA or capillary leak syndrome
- Rocket Pharmaceuticals is engaging with the FDA on pivotal trial; regulatory update expected in H2 2026
- Danon disease program update expected in H2 2026
Source text: ID:nBw9cyXvYa
Further company coverage: RCKT.O
